Re: Limits of predictive models using microarray data for breast cancer clinical treatment outcome.
Jansen
Maurice P H M
MP
Foekens
John A
JA
Klijn
Jan G M
JG
Berns
Els M J J
EM
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000235:genetics; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy*; D017931:DNA Primers; D005260:Female; D018398:Homeodomain Proteins / Q000032:analysis* / Q000235:genetics; D006801:Humans; D046228:Microarray Analysis; D018579:Patient Selection; D011237:Predictive Value of Tests; D011960:Receptors, Estrogen / Q000032:analysis; D018123:Receptors, Interleukin / Q000032:analysis* / Q000235:genetics; D053722:Receptors, Interleukin-17; D012107:Research Design; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D013629:Tamoxifen / Q000627:therapeutic use*; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D017931:DNA Primers; C484414:HOXB13 protein, human; D018398:Homeodomain Proteins; C408922:IL17RB protein, human; D011960:Receptors, Estrogen; D018123:Receptors, Interleukin; D053722:Receptors, Interleukin-17; D013629:Tamoxifen